Latest & greatest articles for glimepiride

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on glimepiride or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on glimepiride and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for glimepiride

1. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes 29947099 2018 07 17 1463-1326 2018 Jun 27 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. 10.1111/dom.13437 To compare the efficacy and safety of dapagliflozin and dapagliflozin plus saxagliptin vs (...) glimepiride as add-on to metformin in patients with type 2 diabetes. This 52-week, multicentre, double-blind, active-controlled study (NCT02471404) randomized (1:1:1) patients (n = 939; HbA1c 7.5%-10.5%) on metformin monotherapy (≥1500 mg/day) to add-on dapagliflozin 10 mg, dapagliflozin 10 mg plus saxagliptin 5 mg, or glimepiride 1 to 6 mg (titrated). The primary efficacy end point was change in HbA1c from baseline to Week 52. Baseline mean age, diabetes duration and HbA1c were 58.4 years, 7.0 years

EvidenceUpdates2018

2. Glimepiride

Glimepiride Top results for glimepiride - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for glimepiride The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

3. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial 29708650 2018 06 06 1463-1326 2018 Apr 30 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator (...) , phase III trial. 10.1111/dom.13340 To compare the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide 1.5 and 0.75 mg with glimepiride in East-Asian patients with type 2 diabetes (T2D). In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d). The primary endpoint was assessment

EvidenceUpdates2018

4. Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride 29907581 2018 06 16 1935-5548 2018 Jun 15 Diabetes care Diabetes Care Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. dc171525 10.2337/dc17-1525 To assess the effect of empagliflozin on bone fractures (...) and bone mineral density in patients with type 2 diabetes in pooled placebo-controlled trial data and a head-to-head study versus glimepiride. Pooled data were analyzed from patients who were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in phase I-III clinical trials. Data were also analyzed from the EMPA-REG H2H-SU trial in which patients received empagliflozin 25 mg or glimepiride as an add-on to metformin for 104 weeks with a 104-week extension. Bone fracture adverse events (AEs) were

EvidenceUpdates2018

5. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin

The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin 26749407 2016 04 13 2017 01 06 2017 01 07 1463-1326 18 5 2016 May Diabetes, obesity & metabolism Diabetes Obes Metab Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. 463-74 10.1111/dom.12629 To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control (...) in patients with type 2 diabetes on metformin or glimepiride background therapy. In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000 mg twice daily versus placebo added to either glimepiride (glimepiride add-on study) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct

EvidenceUpdates2016

6. A 24-week Study to Evaluate the Efficacy and Safety of Once Weekly Dulaglutide Added on to Glimepiride in Type 2 Diabetes (AWARD-8)

A 24-week Study to Evaluate the Efficacy and Safety of Once Weekly Dulaglutide Added on to Glimepiride in Type 2 Diabetes (AWARD-8) 26799540 2016 04 13 2017 01 06 2017 02 20 1463-1326 18 5 2016 May Diabetes, obesity & metabolism Diabetes Obes Metab A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). 475-82 10.1111/dom.12634 To evaluate the safety and efficacy of once-weekly dulaglutide 1.5 mg, a long-acting (...) glucagon-like peptide-1 receptor agonist, compared with placebo in patients with type 2 diabetes (T2D) on glimepiride monotherapy. This phase III, randomized (4 : 1; dulaglutide:placebo), double-blind, placebo-controlled, 24-week study compared the safety and efficacy of once-weekly dulaglutide 1.5 mg with placebo in sulphonylurea-treated (≥half-maximal dose, stable ≥3 months) patients (N = 300) with T2D and inadequate glycaemic control [glycated haemoglobin (HbA1c) ≥7.5 and ≤9.5% (≥58 mmol/mol and ≤80

EvidenceUpdates2016

7. Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety

Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety | CADTH.ca Find the information you need Glyburide, Gliclazide or Glimepiride for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Glyburide, Gliclazide or Glimepiride (...) for Elderly Patients with Type 2 Diabetes: An Updated Review of the Clinical Effectiveness and Safety Published on: August 20, 2015 Project Number: RC0693-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of glyburide versus gliclazide or glimepiride in elderly patients with type 2 diabetes? What is the clinical evidence regarding the safety of glyburide, gliclazide or glimepiride in elderly

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

8. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) 26089386 2015 11 25 2016 06 27 2015 11 25 1935-5548 38 12 2015 Dec Diabetes care Diabetes Care Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). 2241-9 10.2337/dc14-1625 This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like (...) peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks. In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine. The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE

EvidenceUpdates2015

9. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes (...) , or glimepiride (up-titrated to 6 mg or 8 mg per day) orally once daily. Patients, study investigators, and local sponsor personnel were masked to treatment. The primary endpoint was change in HbA1c from baseline to week 52, with a non-inferiority margin of 0·3% for the comparison of each canagliflozin dose with glimepiride. If non-inferiority was shown, we assessed superiority on the basis of an upper bound of the 95% CI for the difference of each canagliflozin dose versus glimepiride of less than 0·0

Lancet2013

10. Randomised controlled trial: Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride

Randomised controlled trial: Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride Article Text Therapeutics

Evidence-Based Medicine (Requires free registration)2013

11. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. 23850055 2013 09 16 2013 09 26 2015 11 19 1474-547X 382 9896 2013 Sep 14 Lancet (London, England) Lancet Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from (...) a randomised, double-blind, phase 3 non-inferiority trial. 941-50 10.1016/S0140-6736(13)60683-2 S0140-6736(13)60683-2 Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with metformin. We undertook this 52 week, randomised, double-blind, active-controlled, phase 3 non

Lancet2013

12. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. 22748821 2012 08 06 2012 08 13 2015 11 19 1474-547X 380 9840 2012 Aug 04 Lancet (London, England) Lancet 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. 475-83 10.1016 (...) /S0140-6736(12)60691-6 Addition of a sulphonylurea to metformin improves glycaemic control in type 2 diabetes, but is associated with hypoglycaemia and weight gain. We aimed to compare a dipeptidyl peptidase-4 inhibitor (linagliptin) against a commonly used sulphonylurea (glimepiride). In this 2-year, parallel-group, non-inferiority double-blind trial, outpatients with type 2 diabetes and glycated haemoglobin A(1c) (HbA(1c)) 6·5-10·0% on stable metformin alone or with one additional oral antidiabetic

Lancet2012

13. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. 22683137 2012 06 18 2012 06 28 2015 06 16 1474-547X 379 9833 2012 Jun 16 Lancet (London, England) Lancet Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. 2270-8 (...) 10.1016/S0140-6736(12)60479-6 Glycaemic control deteriorates progressively over time in patients with type 2 diabetes. Options for treatment escalation remain controversial after failure of first-line treatment with metformin. We compared add-on exenatide with glimepiride for durability of glycaemic control in patients with type 2 diabetes inadequately controlled by metformin alone. We did an open-label, randomised controlled trial at 128 centres in 14 countries between Sept 5, 2006, and March 29

Lancet2012

14. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. 22374408 2012 04 16 2012 05 02 2015 06 16 1474-547X 379 9824 2012 Apr 14 Lancet (London, England) Lancet TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. 1403-11 10.1016/S0140-6736(11)61879-5 Activation of free fatty acid receptor 1 (FFAR1; also known as G-protein-coupled receptor 40 (...) assigned equally to receive placebo, TAK-875 (6·25, 25, 50, 100, or 200 mg), or glimepiride (4 mg) once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary outcome was change in haemoglobin A(1c) (HbA(1c)) from baseline. Analysis included all patients randomly assigned to treatment groups who received at least one dose of double-blind study drug. The trial is registered at ClinicalTrials.gov, NCT01007097. 426 patients were randomly assigned to TAK-875 (n=303

Lancet2012

15. Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety

Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions There was no evidence identified concerning the clinical effectiveness of glyburide when

Health Technology Assessment (HTA) Database.2011

16. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Lee WC, Conner C, Hammer M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of liraglutide (1.2 or 1.8mg) compared with rosiglitazone (4mg), both combined with glimepiride, for the management of adults with type 2 diabetes mellitus. The authors concluded that liraglutide (particularly 1.2mg

NHS Economic Evaluation Database.2011

17. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus

A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the long-term clinical and economic impact of liraglutide versus glimepiride as monotherapies in patients with type 2 diabetes mellitus. The authors concluded that liraglutide

NHS Economic Evaluation Database.2009

18. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. 18819705 2009 02 09 2009 02 19 2015 11 19 1474-547X 373 9662 2009 Feb 07 Lancet (London, England) Lancet Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. 473-81 10.1016/S0140-6736(08)61246-5 New treatments for type 2 diabetes mellitus (...) are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia. We aimed to investigate the safety and efficacy of liraglutide as monotherapy for this disorder. In a double-blind, double-dummy, active-control, parallel-group study, 746 patients with early type 2 diabetes were randomly assigned to once daily liraglutide (1.2 mg [n=251] or 1.8 mg [n=247]) or glimepiride 8 mg (n=248) for 52 weeks. The primary outcome was change in proportion of glycosylated haemoglobin

Lancet2009

19. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. 18378631 2008 04 04 2008 04 07 2016 11 24 1538-3598 299 13 2008 Apr 02 JAMA JAMA Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. 1561-73 10.1001/jama.299.13.1561 No antidiabetic regimen has demonstrated the ability (...) to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers. To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes. Double-blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America

JAMA2008

20. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results (...) of a randomized clinical trial Umpierrez G, Issa M, Vlajnic A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors studied glimepiride and pioglitazone for the treatment of Type 2 diabetes. Glimepiride was given once daily at a starting dose of 2 mg

NHS Economic Evaluation Database.2006